These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 19500021)

  • 1. Distinct genetic alterations in the mitogen-activated protein kinase pathway dictate sensitivity of thyroid cancer cells to mitogen-activated protein kinase kinase 1/2 inhibition.
    Schweppe RE; Kerege AA; Sharma V; Poczobutt JM; Gutierrez-Hartmann A; Grzywa RL; Haugen BR
    Thyroid; 2009 Aug; 19(8):825-35. PubMed ID: 19500021
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential responses of human papillary thyroid cancer cell lines carrying the RET/PTC1 rearrangement or a BRAF mutation to MEK1/2 inhibitors.
    Henderson YC; Fredrick MJ; Clayman GL
    Arch Otolaryngol Head Neck Surg; 2007 Aug; 133(8):810-5. PubMed ID: 17709622
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MEK inhibitor PD0325901 significantly reduces the growth of papillary thyroid carcinoma cells in vitro and in vivo.
    Henderson YC; Chen Y; Frederick MJ; Lai SY; Clayman GL
    Mol Cancer Ther; 2010 Jul; 9(7):1968-76. PubMed ID: 20587665
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibitory effects of the mitogen-activated protein kinase kinase inhibitor CI-1040 on the proliferation and tumor growth of thyroid cancer cells with BRAF or RAS mutations.
    Liu D; Liu Z; Jiang D; Dackiw AP; Xing M
    J Clin Endocrinol Metab; 2007 Dec; 92(12):4686-95. PubMed ID: 17911174
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo.
    Ouyang B; Knauf JA; Smith EP; Zhang L; Ramsey T; Yusuff N; Batt D; Fagin JA
    Clin Cancer Res; 2006 Mar; 12(6):1785-93. PubMed ID: 16551863
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of the growth of papillary thyroid carcinoma cells by CI-1040.
    Henderson YC; Ahn SH; Clayman GL
    Arch Otolaryngol Head Neck Surg; 2009 Apr; 135(4):347-54. PubMed ID: 19380355
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Up-regulation of urinary-type plasminogen activator correlates with high-risk papillary thyroid carcinoma with BRAF(V600E) mutation and its possible molecular mechanism.
    Wakasa T; Li Y; Bai Y; Liu Z; Ozaki T; Mori I; Miyauchi A; Kakudo K; Nakamura M
    Pathol Res Pract; 2014 Nov; 210(11):733-8. PubMed ID: 25085839
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased type 3 deiodinase expression in papillary thyroid carcinoma.
    Romitti M; Wajner SM; Zennig N; Goemann IM; Bueno AL; Meyer EL; Maia AL
    Thyroid; 2012 Sep; 22(9):897-904. PubMed ID: 22823995
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytostatic activity of adenosine triphosphate-competitive kinase inhibitors in BRAF mutant thyroid carcinoma cells.
    Salerno P; De Falco V; Tamburrino A; Nappi TC; Vecchio G; Schweppe RE; Bollag G; Santoro M; Salvatore G
    J Clin Endocrinol Metab; 2010 Jan; 95(1):450-5. PubMed ID: 19880792
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Suppression of BRAF/MEK/MAP kinase pathway restores expression of iodide-metabolizing genes in thyroid cells expressing the V600E BRAF mutant.
    Liu D; Hu S; Hou P; Jiang D; Condouris S; Xing M
    Clin Cancer Res; 2007 Feb; 13(4):1341-9. PubMed ID: 17317846
    [TBL] [Abstract][Full Text] [Related]  

  • 11. KRAS/BRAF mutation status and ERK1/2 activation as biomarkers for MEK1/2 inhibitor therapy in colorectal cancer.
    Yeh JJ; Routh ED; Rubinas T; Peacock J; Martin TD; Shen XJ; Sandler RS; Kim HJ; Keku TO; Der CJ
    Mol Cancer Ther; 2009 Apr; 8(4):834-43. PubMed ID: 19372556
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BRAFV600E mutation is associated with preferential sensitivity to mitogen-activated protein kinase kinase inhibition in thyroid cancer cell lines.
    Leboeuf R; Baumgartner JE; Benezra M; Malaguarnera R; Solit D; Pratilas CA; Rosen N; Knauf JA; Fagin JA
    J Clin Endocrinol Metab; 2008 Jun; 93(6):2194-201. PubMed ID: 18381570
    [TBL] [Abstract][Full Text] [Related]  

  • 13. p53 constrains progression to anaplastic thyroid carcinoma in a Braf-mutant mouse model of papillary thyroid cancer.
    McFadden DG; Vernon A; Santiago PM; Martinez-McFaline R; Bhutkar A; Crowley DM; McMahon M; Sadow PM; Jacks T
    Proc Natl Acad Sci U S A; 2014 Apr; 111(16):E1600-9. PubMed ID: 24711431
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term vemurafenib treatment drives inhibitor resistance through a spontaneous KRAS G12D mutation in a BRAF V600E papillary thyroid carcinoma model.
    Danysh BP; Rieger EY; Sinha DK; Evers CV; Cote GJ; Cabanillas ME; Hofmann MC
    Oncotarget; 2016 May; 7(21):30907-23. PubMed ID: 27127178
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activation of the RAS/RAF/ERK signaling pathway contributes to resistance to sunitinib in thyroid carcinoma cell lines.
    Piscazzi A; Costantino E; Maddalena F; Natalicchio MI; Gerardi AM; Antonetti R; Cignarelli M; Landriscina M
    J Clin Endocrinol Metab; 2012 Jun; 97(6):E898-906. PubMed ID: 22442268
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MAPK and SHH pathways modulate type 3 deiodinase expression in papillary thyroid carcinoma.
    Romitti M; Wajner SM; Ceolin L; Ferreira CV; Ribeiro RV; Rohenkohl HC; Weber Sde S; Lopez PL; Fuziwara CS; Kimura ET; Maia AL
    Endocr Relat Cancer; 2016 Mar; 23(3):135-46. PubMed ID: 26825960
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lack of association between BRAF V600E mutation and mitogen-activated protein kinase activation in papillary thyroid carcinoma.
    Zuo H; Nakamura Y; Yasuoka H; Zhang P; Nakamura M; Mori I; Miyauchi A; Kakudo K
    Pathol Int; 2007 Jan; 57(1):12-20. PubMed ID: 17199737
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Ca2+-calmodulin-dependent kinase II is activated in papillary thyroid carcinoma (PTC) and mediates cell proliferation stimulated by RET/PTC.
    Rusciano MR; Salzano M; Monaco S; Sapio MR; Illario M; De Falco V; Santoro M; Campiglia P; Pastore L; Fenzi G; Rossi G; Vitale M
    Endocr Relat Cancer; 2010 Mar; 17(1):113-23. PubMed ID: 19903742
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dual inhibition of mitogen-activated protein kinase kinase and mammalian target of rapamycin in differentiated and anaplastic thyroid cancer.
    Jin N; Jiang T; Rosen DM; Nelkin BD; Ball DW
    J Clin Endocrinol Metab; 2009 Oct; 94(10):4107-12. PubMed ID: 19723757
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BRAF-activated LncRNA functions as a tumor suppressor in papillary thyroid cancer.
    Liao T; Qu N; Shi RL; Guo K; Ma B; Cao YM; Xiang J; Lu ZW; Zhu YX; Li DS; Ji QH
    Oncotarget; 2017 Jan; 8(1):238-247. PubMed ID: 27462868
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.